MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today shared an important milestone for its target acquisition, Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (“Appili”), announcing that the U.S.

加利福尼亚州山景城讯（商业新闻短讯）--Aditxt，Inc.（纳斯达克：ADTX）（“Aditxt”或“公司”）是一家致力于加速有前途的健康创新的社会创新平台，今天分享了其收购目标Appili Therapeutics Inc.（TSX:APLI；OTCPink:APLIF）（“Appili”）的重要里程碑，宣布美国。

Food and Drug Administration (“FDA”) has provided positive feedback regarding the development strategy for ATI-1801. For additional information, please visit https://finance.yahoo.com/quote/APLIF/news/..

美国食品和药物管理局（“FDA”）就ATI-1801的开发策略提供了积极的反馈。有关更多信息，请访问https://finance.yahoo.com/quote/APLIF/news/..

About Appili Therapeutics, Inc.

关于Appili Therapeutics，Inc。

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfil its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives.

Appili Therapeutics是一家传染病生物制药公司，旨在建立，投资组合驱动，专注于实现其解决威胁生命的感染的使命。通过系统地识别未满足需求的紧急感染，阿皮利的目标是战略性地开发一系列新疗法，以预防死亡和改善生活。

The Company is currently advancing a diverse range of anti-infectives, including an FDA approved ready-made suspension of metronidazole for the treatment of antimicrobial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease.

该公司目前正在开发多种抗感染药物，包括FDA批准的用于治疗抗菌感染的甲硝唑现成混悬液，用于消除严重生物武器威胁的候选疫苗，以及用于治疗毁容疾病的局部抗寄生虫药。

Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information, visit www.AppiliTherapeutics.com..

由一支经验丰富的管理团队领导，阿皮利正处于全球抗击感染的中心。欲了解更多信息，请访问www.AppiliTherapeutics.com。

About Aditxt, Inc.

关于Adittxt，股份有限公司。

Aditxt, Inc.® is a social innovation platform dedicated to accelerating promising health innovations. Aditxt’s ecosystem of research institutions, industry partners, and shareholders collaboratively drives their mission to 'Make Promising Innovations Possible Together.' The innovation platform is the cornerstone of Aditxt’s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges.

Aditxt，Inc.®是一个社会创新平台，致力于加速有前途的健康创新。ADIXT由研究机构、行业合作伙伴和股东组成的生态系统共同推动他们的使命，使有希望的创新成为可能创新平台是ADIXT战略的基石，在该战略中，多学科推动了颠覆性增长，并解决了重大的社会挑战。

Aditxt operates a unique model that democratizes innovation, ensures every stakeholder’s voice is heard and valued, and empowers collective progress..

ADIXT采用了一种独特的模式，使创新民主化，确保每个利益相关者的声音都能被听到和重视，并促进集体进步。

Aditxt currently operates two programs focused on immune health and precision health. The Company plans to introduce two additional programs dedicated to public health and women’s health. For these, Aditxt has entered into an Arrangement Agreement with Appili Therapeutics, Inc. (“Appili”) (TSX: APLI; OTCPink: APLIF), which focuses on infectious diseases, and a Merger Agreement with Evofem Biosciences, Inc (“Evofem”) (OTCQB:EVFM).

ADIXTT目前运营着两个专注于免疫健康和精准健康的项目。该公司计划推出另外两个专门针对公共卫生和妇女健康的项目。

Each program will be designed to function autonomously while collectively advancing Aditxt’s mission of discovering, developing, and deploying innovative health solutions to tackle some of the most urgent health challenges. The closing of each of the transactions with Appili and Evofem is subject to several conditions, including but not limited to approval of the transactions by the respective target shareholders and Aditxt raising sufficient capital to fund its obligations at closing.

每个项目将被设计为自主运作，同时共同推进ADIXT的使命，即发现、开发和部署创新的健康解决方案，以应对一些最紧迫的健康挑战。与Appili和Evofem的每笔交易的结束都要符合几个条件，包括但不限于各自目标股东对交易的批准，以及ADIXT在结束时筹集足够的资本来为其义务提供资金。

No assurance can be provided that all of the conditions to closing will be obtained or satisfied or that either of the transactions will ultimately close..

无法保证将获得或满足所有成交条件，或任何一笔交易最终将成交。

For more information, www.aditxt.com.

有关更多信息，请访问www.aditxt.com。

Follow us on:

关注我们：

LinkedIn: https://www.linkedin.com/company/aditxt

LinkedIn: https://www.linkedin.com/company/aditxt

Facebook: https://www.facebook.com/aditxtplatform/

Facebook: https://www.facebook.com/aditxtplatform/

Forward-Looking Statements

前瞻性声明

Certain statements in this press release constitute “forward-looking statements” within the meaning of federal securities laws. Forward-looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company’s ongoing and planned product and business development; the Company’s ability to finance and execute its strategic M&A initiatives; the Company’s ability to obtain the necessary funding and partner to commence clinical trials; the Company’s intellectual property position; the Company’s ability to develop commercial functions; expectations regarding product launch and revenue; the Company’s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth, and strategies; the Company’s ability to raise additional capital; the industry in which the Company operates; and the trends that may affect the industry or the Company.

本新闻稿中的某些声明构成联邦证券法所指的“前瞻性声明”。前瞻性陈述包括关于公司意图、信念、预测、前景、分析或当前期望的陈述，其中包括公司正在进行和计划中的产品和业务发展；公司融资和执行战略并购计划的能力；公司获得必要资金和合作伙伴开始临床试验的能力；公司的知识产权地位；；对产品发布和收入的期望；公司的经营成果、现金需求、支出、财务状况、流动性、前景、增长和战略；公司筹集额外资本的能力；公司经营的行业；以及可能影响行业或公司的趋势。

Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as market and other conditions and those risks more fully discussed in the section titled “Risk Factors” in Aditxt’s most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s other filings with the Securities and Exchange Commission.

前瞻性陈述并不能保证未来的业绩，由于各种重要因素、市场和其他条件以及ADIXT最新10-K表年度报告中标题为“风险因素”的部分中更充分讨论的风险，以及公司向证券交易委员会提交的其他文件中对潜在风险、不确定性和其他重要因素的讨论，实际结果可能与这些前瞻性陈述所显示的结果存在重大差异。

All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law..

所有此类声明仅在作出之日发表，公司没有义务公开更新或修改任何前瞻性声明，无论是由于新信息、未来事件还是其他原因，除非法律要求。